Instructions for Milgamma (Pyridoxine, Thiamine, Cyanocobalamin, Lidocaine)
Release Form:
p-r d/v/m introduction of 100 mg+100 mg+1 mg+20 mg/2 ml: Amp. 5, 10 or 25 pcs.
Description:
The solution for injection is transparent, red, with a characteristic smell.
1 amp
tiamine hydrochloride 100 mg
pyridoxine hydrochloride 100 mg
cyanocobalamine 1 mg
Lidocain hydrochloride 20 mg
Auxiliary substances: benzyl alcohol - 40 mg, sodium polyphosphate - 20 mg, potassianoferrat - 0.2 mg, sodium hydroxide - 12 mg, water for injection - up to 2 ml.
A white dot is applied to the ampoule.
ATX codes
A11DB Vitamin B
N07X Other drugs Milgamma for treatment of nervous system diseases
Pharmacological groups / Group membership:
B vitamin complex
Active substance:
lidokain hydrochloride
pyridoxine hydrochloride
cyanocobalamine
tiamine hydrochloride
Pharmacy Group
B+Other vitamins
Retention Terms:
The drug Milgamma should be stored in a light-protected place not accessible to children
Shelf life
Shelf life - 3 years. Do not use after expiration.
Pharmaceuticals
Pharmacodynamics:
Neurotropic vitamins of Group B have a favorable effect on inflammatory and degenerative diseases of the nerves and the motor apparatus. They help to increase blood flow and improve the work of the nervous system.
Tiamine plays a key role in carbohydrate metabolism, as well as in the Krebs cycle with subsequent participation in synthesis of TPF (tiamine pyrophosphate) and ATF (adenosis triphosphate).
Piridoxine is involved in protein metabolism, and partly in carbohydrate and fat metabolism. The physiological function of both vitamins is the potentiality of each other's actions, manifested in positive effects on the nervous, neuromuscular and cardiovascular systems. With vitamin B6 deficiency, widespread deficiency conditions quickly buy out when these vitamins are introduced.
Cyanocobalamine participates in the synthesis of myeline membrane, stimulates hemopoesis, reduces pain associated with the peripheral nervous system, stimulates nucleic exchange through the activation of folic acid.
Lidokain is a local anesthesitic that causes all kinds of local anesthesia: terminal, infiltration, conductive.
Testimonials:
- As a pathogenetic and symptomatic agent in the complex therapy of diseases and neurosystem syndromes of different origins:
- neuralgia, neuritis;
- facial nerve grooves;
- retrobulb neurite;
- ganglionites (including the rounding fox);
- plexopathy;
- neuropathy, polyeuropathy (diabetic, alcoholic, etc.);
- night muscle cramps, especially in older age groups;
- Neurological manifestations of osteochondrosis of the spine: radiculopathy, lumboishalgia, musculotonic syndromes.
- Method of application, course and dosage
- Injections are performed deep in/m.
In cases of expressed pain syndrome for rapid achievement of high level of the drug in the blood treatment it is advisable to start with 2 ml daily for 5-10 days. After the pain syndrome and lung forms of the disease, they are then either treated with a drug Milgamma form for injection (e.g., Milgamma composite) or with less frequent injections (2-3 times a week for 2-3 weeks), with the possible continuation of the drug therapy for intravenous treatment (e.g. Milgamma composite).
Weekly control of therapy by the doctor is recommended.
The transition to therapy with a drug Milgamma form for inward treatment (e.g., Milgammacomposite) is recommended to be carried out in the shortest possible time
Overdose:
The treatment of overdose consists in canceling the drug Milgamma and carrying out symptomatic therapy.
Drug Interaction:
Tiamine is completely dissolved in solutions containing sulfites, as a result, the products of decay of tiamine inactivate the actions of other vitamins.
Tiamine is incompatible with oxidizing and regenerative compounds, including iodides, carbonates, acetates, tanic acid, iron ammonium cytrat, phenobarbital, riboflate wine, benzilpenicillin, decstrosis, disulfitis and others.
Copper accelerates the destruction of tiamine; In addition, tiamine loses its effectiveness by increasing the pH values (more than 3).
Therapeutic doses of pyridoxine weaken the effect of the levodope (the anti-parkinsonic effect of the levodope is reduced) at the same time. There is also interaction with cycloserine, penicillamine, isoniazide.
In the case of the parenteral application of lidokain in case of additional use of norepinephrine and epinephrine, it is possible to increase the side effect on the heart. There is also interaction with sulfonamides.
Cyanocobalamine is incompatible with heavy metal salts. Riboflavin also has destructive effects, especially when light is simultaneously exposed; nicotinamide accelerates the photolysis, while antioxidants have an inhibent effect.
Use in pregnancy and breastfeeding
The use of the drug Milgamma is contraindicated during pregnancy and breastfeeding.
Side Action:
The frequency of adverse side reactions is reported according to the WHO classification: Very often (more than 1 in 10 treatments), often (less than 1 in 10, but more than 1 in 100 treatments), rarely (less than 1 in 1,000, but more than 1 in 1,000), rarely (less than 1 in 1,000 but more than 1 in 10,000 treated), very rare (less than 1 in 10,000, including individual cases), and in some cases - symptoms appear with an unknown frequency.
Application of children
Contradicted use of the drug Milgamma in childhood.
Nozology Milgamma
B02.2
Tightening fox with other complications from the nervous system
G50.0
Neuralgia triple nerve
G51
Facial nerve damage
G53.0
Neuralgia after the enclosing lichen (B02.2)
G54
Nervous spine and gossip lesions
G58.9
Mononeuropathy Unspecified
G60
Hereditary and idiopathic neuropathy
G61
Inflammatory Polyeuropathy
G62.1
Alcohol Polyeuropa
G63.2
Diabetic Polyeuropathy
H46
Neuritus optic nerve
M42
Osteochondrosis of the spine
M54.1
Radiculopathy
M54.3
Ishias
M54.4
Lumbago with Ishias
M79.1
Milgia
M79.2
Neuralgia and Neuritius Unspecified
R25.2
Spas and Spasms
